Fypion Fypion
November 13, 2026 · Lead Generation

FAQ: Why a Supplement Brand's Contract Manufacturer Is Its Biggest Unmanaged FDA Risk

A supplement brand’s product liability insurer asks a simple question during a routine policy renewal: when was the contract manufacturer’s facility last inspected, and what did FDA find? The brand doesn’t know. Nobody on staff has looked at that manufacturer’s inspection history since the vendor onboarding call two years ago, and in the meantime that facility picked up a warning letter over an identity-testing gap that has nothing to do with this brand’s specific formula - but everything to do with whether its product is legally adulterated right now.

If the brand didn’t make the product, why is it on the hook?

Under 21 CFR Part 111, the name on the label carries the legal responsibility for cGMP compliance, not the entity that ran the equipment. FDA sends warning letters to the facility, but an adulteration finding - unresolved foreign material, failed identity testing, a missing specification - makes the finished product itself illegal to sell. That’s the brand’s problem the moment its name is on the bottle.

What gets cited most in FDA’s letters to contract manufacturers?

A small, repeating set of failures: equipment not properly maintained or connected during filling, inadequate identity testing on incoming components, specifications under 111.70 that don’t exist or don’t hold up, and corrective-action responses that claim a fix without documented proof it was implemented and verified. None of it is exotic - it’s the basic paper trail a working quality system produces on its own.

Why isn’t a manufacturer’s compliance certificate enough?

A certificate says a manufacturer believed it met a spec at one point in time. It says nothing about an open warning letter, an unresolved 483, or a pattern across inspection cycles. Coverage of recent FDA actions has specifically flagged brands that took a contractor’s paperwork at face value instead of pulling that contractor’s actual inspection history - a gap that surfaces only once the brand’s own product is named in an action, much like a compounding pharmacy discovering its beyond-use date is a legal argument, not a shelf-life estimate, only after something goes wrong downstream of a paper assumption.

What changes when a brand uses several contract manufacturers?

Each one runs an independent quality system, gets inspected on its own schedule, and builds its own 483 and warning-letter history - there’s no shared record across facilities. A brand split across three manufacturers is managing three separate FDA risk profiles, and a citation at one won’t show up anywhere near the other two unless someone is actively checking all three against the same standard, a problem CPG and consumer brands running co-packed and white-labeled lines increasingly can’t manage in a spreadsheet.

What finally gets a brand to put real oversight in place?

Rarely a routine reorder. More often it’s a contract manufacturer’s facility drawing a warning letter after the brand’s product already shipped under that manufacturer’s batch records, a retail or marketplace partner requiring documented supplier qualification before listing the product, or a liability claim that exposes how little the brand actually knew about its manufacturer’s current standing.

Talk to us if your outbound to supplement brands still pitches generic formulation or inventory software instead of the contract-manufacturer compliance visibility that decides whether their product is legally sellable.

Ready to fill your calendar with qualified meetings?

Pay only for meetings you confirm were a good fit.

book a call →